These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28619439)

  • 41. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals.
    Mourez T; Decroos A; Goria O; Montialoux H; De Oliveira F; Larrat S; Plantier JC; Riachi G
    J Med Virol; 2018 May; 90(5):994-997. PubMed ID: 29350410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.
    Peiffer KH; Kuhnhenn L; Stelzl E; Dietz J; Susser S; Tal AO; Finkelmeier F; Zuckerman E; Cornberg M; Barak M; Piazzolla V; Mangia A; Zeuzem S; Kessler HH; Vermehren J; Sarrazin C
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.
    Borgia SM; Hedskog C; Parhy B; Hyland RH; Stamm LM; Brainard DM; Subramanian MG; McHutchison JG; Mo H; Svarovskaia E; Shafran SD
    J Infect Dis; 2018 Oct; 218(11):1722-1729. PubMed ID: 29982508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.
    Hu Z; Liu Y; Qiu L; Fan Z; Nie W; Liang S; Jin R
    Virol J; 2015 Dec; 12():220. PubMed ID: 26684004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.
    Vijgen L; Thys K; Vandebosch A; Van Remoortere P; Verloes R; De Meyer S
    Virol J; 2017 May; 14(1):101. PubMed ID: 28569206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients.
    Aziz H; Aziz M; Gill ML
    Viral Immunol; 2018 Apr; 31(3):256-263. PubMed ID: 29664710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.
    Yang S; Xing H; Feng S; Ju W; Liu S; Wang X; Ou W; Cheng J; Pan CQ
    Arch Virol; 2018 Feb; 163(2):467-473. PubMed ID: 29143142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?
    Yukawa Y; Tamori A; Iio E; Ogawa S; Yoshida K; Uchida-Kobayashi S; Enomoto M; Tanaka Y; Kawada N
    Clin J Gastroenterol; 2019 Dec; 12(6):598-602. PubMed ID: 31165460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage.
    Hostager R; Ragonnet-Cronin M; Murrell B; Hedskog C; Osinusi A; Susser S; Sarrazin C; Svarovskaia E; Wertheim JO
    Virus Evol; 2019 Jul; 5(2):vez041. PubMed ID: 31616569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of circulating HCV recombinant form RF1_2k/1b in blood serum of patients by real-time RT-PCR.
    Akimov IA; Timofeev DI; Mavzyutov AR; Ivanov MK
    Klin Lab Diagn; 2021 Mar; 66(2):122-128. PubMed ID: 33734647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis.
    Alves da Silva R; de Souza Todão J; Kamitani FL; Silva AEB; de Carvalho-Filho RJ; Ferraz MLCG; de Carvalho IMVG
    J Med Virol; 2018 Mar; 90(3):537-544. PubMed ID: 29064576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b.
    Zakalashvili M; Zarkua J; Gish RG; Zhamutashvili M; Sartania V; Weizenegger M; Bartel J; Raabe M; Gvinjilia L; Metreveli S; Barnova M; Abramishvili N; Rtskhiladze I; Metreveli D
    Hepatol Res; 2021 Feb; 51(2):156-165. PubMed ID: 33207029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful Hepatitis C Virus Eradication in a Hemodialysis Patient With 2k/1b Chimera Genotype: A Case Report and Literature Review.
    Zubkin ML; Shchepetkova GS; Balkarova OV; Chervinko VI; Kryukov EV
    Gastroenterology Res; 2019 Jun; 12(3):176-180. PubMed ID: 31236161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries].
    Simon KG; Serfert Y; Buggisch P; Mauss S; Boeker KHW; Klinker H; Müller T; Merle U; Hüppe D; Manns MP; Wedemeyer H
    Z Gastroenterol; 2021 Mar; 59(3):241-249. PubMed ID: 33684956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.